GL1X · GenesisL1 explorer

MolNFT v1 · #20994 · protein

Crystal structure of human caspase-1 in complex with 3-{2-ethyl-6-[4- (quinoxalin-2-ylamino)-benzoylamino]-hexanoylamino}-4-oxo-butyric acid

1RWN · Interleukin-1 beta convertase: “Crystal structure of human caspase-1 in complex with 3-{2-ethyl-6-[4…”. X-ray diffraction, 1 ligand (4QB), 2 pockets (best druggability 0.52). MolNFT v1 #20994 on GenesisL1: 3D structure, binding…

PDB
1RWN
Type
protein
Length
261 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Interleukin-1 beta convertase
EC
3.4.22.36
UniProt
P29466
Ligands
4QB
Pockets
2 · best druggability 0.52

Structure

x-ray diffraction · 2 distinct chains · 29% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AInterleukin-1 beta convertase (EC 3.4.22.36)protein17330% helix, 19% strandP29466
BInterleukin-1 beta convertase (EC 3.4.22.36)protein8827% helix, 16% strandP29466

Ligands and binding sites

  • 4QB · 3-{2-ethyl-6-[4-(quinoxalin-2-ylamino)-benzoylamino]-hexanoylamino}-4-oxo-butyric acid · ligand · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1650.520.8620empty
2580.320.7618empty

Interfaces

1 interface between chains.

  • A–B · 2720 Ų buried · 52 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 1RWN · Crystal structure of human caspase-1 in complex with… · the same entry in another collection · chain A against A, TM-score 1.00
  • P29466 · AlphaFold monomer V2.0 prediction for caspase-1 (P29466) · a predicted model of the same protein · chain B against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.